Pseudomonas aeruginosa treatment and transmission reduction

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 8, 2013, Pages 831-837

  Bowers, Dana R ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

antimicrobial stewardship; Gram negative bacteria; infection control; nonfermenter; resistance surveillance; therapy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; CORTICOSTEROID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYMYXIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL MENINGITIS; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BLOOD CULTURE; CENTRAL NERVOUS SYSTEM INFECTION; CONTINUOUS INFUSION; DEBRIDEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION RISK; MAXIMUM PLASMA CONCENTRATION; MICROBIAL ACTIVITY; MICROBIAL COMMUNITY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; OPTIMAL DRUG DOSE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUANTITATIVE DIAGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION;

ANTI-INFECTIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK ASSESSMENT; TIME FACTORS;

EID: 84887572050     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.816463     Document Type: Review

References (59)

1. Marshall JC, Maier RV, Jimenez M et al. Source control in the management of severe sepsis and sePTic shock: An evidence-based review. Crit. Care Med. 32(11 Suppl.), S513-526 (2004
2. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 284(5418), 1318-1322 (1999
3. Ferreira AS, Silva IN, Oliveira VH et al. Comparative transcriPTomic analysis of the burkholderia cepacia tyrosine kinase bcef mutant reveals a role in tolerance to stress, biofilm formation, and virulence. Appl. Environ. Microbiol. 79(9), 3009-3020 (2013
4. Guidelines for the management of adults with hospital-Acquired, ventilator-Associated, and healthcare-Associated pneumonia. Am. J. Respir. Crit. Care Med. 171(4), 388-416 (2005
5. Lipsky BA, Berendt AR, Cornia PB et al. 2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 54(12), e132-173 (2012
6. Tumbarello M, Repetto E, Trecarichi EM et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: Risk factors and mortality. Epidemiol. Infect. 139(11), 1740-1749 (2011
7. Bates DW, Lee TH. Rapid classification of positive blood cultures. Prospective validation of a multivariate algorithm. JAMA. 267(14), 1962-1966 (1992
8. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator- Associated pneumonia: A pilot study. Am. J. Respir. Crit. Care Med. 157(2), 371-376 (1998
9. Ruiz M, Torres A, Ewig S et al. Noninvasive versus invasive microbial investigation in ventilator-Associated pneumonia: Evaluation of outcome. Am. J. Respir. Crit. Care Med. 162(1), 119-125 (2000
10. Sole Violan J, Fernandez JA, Benitez AB et al. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia. Crit. Care Med. 28(8), 2737-2741 (2000
11. Fagon JY, Chastre J, Wolff M et al. Invasive and noninvasive strategies for management of suspected ventilator-Associated pneumonia. A randomized trial. Ann. Intern. Med. 132(8), 621-630 (2000
12. Kwon Y, Milbrandt EB, Yende S. Diagnostic techniques for ventilator-Associated pneumonia: Conflicting results from two trials. Crit. Care 13(3), 303 (2009
13. Kang CI, Kim SH, Kim HB et al. Pseudomonas aeruginosa bacteremia: Risk factors for mortality and influence of delayed receiPT of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37(6), 745-751 (2003
14. Lodise TP Jr, Patel N, Kwa A et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: Impact of delayed appropriate antibiotic selection. Antimicrob. Agents Chemother. 51(10), 3510-3515 (2007
15. Cheong HS, Kang CI, Wi YM et al. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur. J. Clin. Microbiol. Infect. Dis. 27(12), 1219-1225 (2008
16. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin. Infect. Dis. 34(5), 634-640 (2002
17. Tam VH, Chang KT, Abdelraouf K et al. Prevalence, resistance mechanisms, and suscePTibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54(3), 1160-1164 (2010
18. Tam VH, Chang KT, LaRocco MT et al. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn. Microbiol. Infect Dis. 58(3), 309-314 (2007
19. Micek ST, Lloyd AE, Ritchie DJ et al. Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 49(4), 1306-1311 (2005
20. Hilf M, Yu VL, Sharp J et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am. J. Med. 87(5), 540-546 (1989
21. Bowers DR, Liew YX, Lye DC et al. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 57(3), 1270-1274 (2013
22. Anderson DJ, Miller B, Marfatia R et al. Ability of an antibiogram to predict Pseudomonas aeruginosa suscePTibility to targeted antimicrobials based on hospital day of isolation. Infect. Control. Hosp. Epidemiol. 33(6), 589-593 (2012
23. Cattoir V, Gilibert A, Le Glaunec JM et al. Rapid detection of Pseudomonas aeruginosa from positive blood cultures by quantitative pcr. Ann. Clin. Microbiol. Antimicrob. 9, 21 (2010
24. Della-Latta P, Salimnia H, Painter T et al. Identification of escherichia coli, klebsiella pneumoniae, and Pseudomonas aeruginosa in blood cultures: A multicenter performance evaluation of a three-color pePTide nucleic acid fluorescence in situ hybridization assay. J. Clin. Microbiol. 49(6), 2259-2261 (2011
25. Schaumann R, Knoop N, Genzel GH et al. A step towards the discrimination of beta-lactamase-producing clinical isolates of enterobacteriaceae and Pseudomonas aeruginosa by MALDI-ToF mass spectrometry. Med. Sci. Monit. 18(9), MT71-77 (2012
26. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactamaminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-Analysis. BMJ. 326(7399), 1111 (2003
27. Paul M, Benuri-Silbiger I, Soares-Weiser K et al. Beta lactam monotherapy versus beta lactam-Aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-Analysis of randomised trials. BMJ. 328(7441), 668 (2004
28. Garnacho-Montero J, Sa-Borges M, Sole-Violan J et al. OPTimal management therapy for Pseudomonas aeruginosa ventilator-Associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit. Care Med. 35(8), 1888-1895 (2007
29. Bliziotis IA, Petrosillo N, Michalopoulos A et al. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia. PLoS One 6(10), e26470 (2011
30. Chamot E, Boffi El Amari E, Rohner P et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47(9), 2756-2764 (2003
31. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Infect Dis. 26(1), 1-10; quiz 11-12 (1998
32. Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39(3), 650-655 (1995
33. Murry KR, McKinnon PS, Mitrzyk B et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 19(11), 125-1260 (1999
34. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-Tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis. 44(3), 357-363 (2007
35. Felton TW, Hope WW, Lomaestro BM et al. Population pharmacokinetics of extended-infusion piperacillin-Tazobactam in hospitalized patients with nosocomial infections. Antimicrob. Agents Chemother. 56(8), 4087-4094 (2012
36. Yost RJ, Cappelletty DM. The retrospective cohort of extended-infusion piperacillin-Tazobactam (receiPT) study: A multicenter study. Pharmacotherapy 31(8), 767-775 (2011
37. Taccone FS, Cotton F, Roisin S et al. OPTimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa sePTic shock. Antimicrob. Agents Chemother. 56(4), 2129-2131 (2012
38. Roberts JA, Kirkpatrick CM, Roberts MS et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte carlo dosing simulations and subcutaneous tissue distribution. J. Antimicrob. Chemother. 64(1), 142-150 (2009
39. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin. Infect. Dis. 52(10), 1232-1240 (2011
40. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-Associated pneumonia in adults: A randomized trial. JAMA. 290(19), 2588-2598 (2003
41. Christ-Crain M, Opal SM. Clinical review: The role of biomarkers in the diagnosis and management of community-Acquired pneumonia. Crit. Care 14(1), 203 (2010
42. Povoa P, Salluh JI. Biomarker-guided antibiotic therapy in adult critically ill patients: A critical review. Ann. Intensive Care 2(1), 32 (2012
43. Michalopoulos A, Papadakis E. Inhaled anti-infective agents: Emphasis on colistin. Infection 38(2), 81-88 (2010
44. Palmer LB, Smaldone GC, Chen JJ et al. Aerosolized antibiotics and ventilatorassociated tracheobronchitis in the intensive care unit. Crit. Care Med. 36(7), 2008-2013 (2008
45. Satlin MJ, Kubin CJ, Blumenthal JS et al. Comparative effectiveness of aminoglycosides, polymyxin b, and tigecycline for clearance of carbapenem-resistant klebsiella pneumoniae from urine. Antimicrob. Agents Chemother. 55(12), 5893-5899 (2011
46. Kwa AL, Loh C, Low JG et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 41(5), 754-757 (2005
47. Michalopoulos A, Falagas ME. Colistin and polymyxin b in critical care. Crit. Care Clin. 24(2), 377-391, x (2008
48. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: A systematic review of the available evidence. Int. J. Antimicrob. Agents 29(1), 9-25 (2007
49. Jacobsen F, Fisahn C, Sorkin M et al. Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant staphylococcus aureus. Antimicrob. Agents Chemother. 55(5), 2325-2334 (2011
50. Pathengay A, Mathai A, Shah GY et al. Intravitreal piperacillin/ tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis. J. Cataract. Refract. Surg. 36(12), 2210-2211 (2010
51. Vincent JL, Gerlach H. Fluid resuscitation in severe sepsis and sePTic shock: An evidence-based review. Crit. Care Med. 32(11 Suppl.), S451-454 (2004
52. Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and sePTic shock: An evidence-based review. Crit. Care Med. 32(11 Suppl.), S527-533 (2004
53. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and sePTic shock: 2012. Crit. Care Med. 41(2), 580-637 (2013
54. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44(2), 159-177 (2007
55. Ntagiopoulos PG, Paramythiotou E, Antoniadou A et al. Impact of an antibiotic restriction policy on the antibiotic resistance patterns of gram-negative microorganisms in an intensive care unit in greece. Int. J. Antimicrob. Agents 30(4), 360-365 (2007
56. Cook PP, Das TD, Gooch M et al. Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa suscePTibility to quinolones and other antimicrobial agents. Infect. Control. Hosp. Epidemiol. 29(8), 716-722 (2008
57. Jonas D, Meyer E, Schwab F et al. Genodiversity of resistant Pseudomonas aeruginosa isolates in relation to antimicrobial usage density and resistance rates in intensive care units. Infect. Control. Hosp. Epidemiol. 29(4), 350-357 (2008
58. Moolenaar RL, Crutcher JM, San Joaquin VH et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: Did staff fingernails play a role in disease transmission? Infect. Control. Hosp. Epidemiol. 21(2), 80-85 (2000
59. Centers for Disease Control and Prevention. Pseudomonas aeruginosa respiratory tract infections associated with contaminated ultrasound gel used for transesophageal echocardiography -Michigan, December 2011-January 2012. MMWR Morb. Mortal. Wkly. Rep. 61, 262-264 (2012